Peripheral neuropathy in HIV: Prevalence and risk factors

AIDS

Volumn 25, Issue 7, 2011, Pages 919-928

  Evans, Scott R ^a   Ellis, Ronald J ^b   Chen, Huichao ^a   Yeh, Tzu Min ^a   Lee, Anthony J ^a   Schifitto, Giovanni ^c   Wu, Kunling ^a   Bosch, Ronald J ^a   McArthur, Justin C ^d   Simpson, David M ^e   Clifford, David B ^f  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f WASHINGTON UNIVERSITY   (United States)

Author keywords

Aging; antiretroviral therapy; HIV; neurological; peripheral neuropathy; risk factors

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; VIRUS RNA;

ADULT; AGE DISTRIBUTION; ANAMNESIS; ARTICLE; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL NEUROPATHY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; PREVALENCE; RISK FACTORS; RNA, VIRAL; YOUNG ADULT;

EID: 79954697705     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328345889d     Document Type: Article

References (43)

1. Keswani SC, Pardo CA, Cherry CL, Hoke A, McArthur JC. HIV-associated sensory neuropathies. AIDS 2002; 16:2105-2117. (Pubitemid 35387264)
2. Bacellar H, Munoz A, Miller EN, Cohen BA, Besley D, Selnes OA, et al. Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992. Neurology 1994; 44:1892-1900. (Pubitemid 24319217)
3. McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol 2005; 4:543-555. (Pubitemid 41139976)
4. Ellis R, Rosario D, Clifford D, McArthurJ, Simpson D, Alexander T, et al. Persisting high prevalence of HIV distal sensory peripheral neuropathy in the era of cART: correlates in the CHARTER study [Paper #461]. CROI 2009; Montreal, Canada.
5. Wulff EA, Wang AK, Simpson DM. HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment. Drugs 2000; 59:1251-1260. (Pubitemid 30410143)
6. Cornblath DR, McArthurJC. Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex. Neurology 1988; 38:794-796.
7. Schifitto G, McDermott MP, McArthurJC, Marder K, Sacktor N, McClernon DR, et al. Markers of immune activation and viral load in HIV-associated sensory neuropathy. Neurology 2005; 64:842-848. (Pubitemid 40316323)
8. Forna F, Liechty C, Solberg P, Asiimwe F, Were W, Mermin J, et al. Early clinical toxicity to nonnucleoside reverse transcrip-tase inhibitor-based HAART in a home-based AIDS care pro-gram inrural Uganda [Abstract#142]. CROI2006; Denver, CO.
9. Kim A, Ngan'ga L, Macharia D, Wangai M, Ilako F, Isavwa A, et al. Adverse events in HIV-infected patients receiving ART in a treatment program in a Nairobi slum, Kenya, 2003 to 2005 [Abstract #143]. CROI 2006; Denver, CO.
10. Simpson DM, Kitch D, Evans SR, McArthur JC, Asmuth DM, Cohen B, et al. HIV neuropathy natural history cohort study: assessment measures and riskfactors. Neurology2006; 66:1 679-1687. (Pubitemid 43964622)
11. Barohn RJ, Gronseth GS, LeForce BR, McVey AL, McGuire SA, Butzin CA. Peripheral nervous system involvement in a large cohortof human immunodeficiency virus-infected individuals. Arch Neurol 1993; 50:167-171. (Pubitemid 23054800)
12. GriffinJW, CrawfordTO, McArthurJC. Peripheral neuropathies associated with HIV infection. In: Gendelman HE, Epstein E, Lipton SA, Swindells S, editors. The neurology of AIDS. New York: Chapman & Hall; 1998. pp. 275-291.
13. Brinkman K, Hofstede J, Burger D, Smeitink J, Koopmans P. Adverse effects of reverse transcriptase inhibitors: mitochon-drial toxicity as common pathway. AIDS 1998; 12:1735-1744. (Pubitemid 28454438)
14. Brew BJ, Tisch S, Law M. Lactate concentrations distinguish between nucleoside neuropathy and HIV neuropathy. AIDS 2003; 17:1094-1096. (Pubitemid 36549727)
15. Cherry CL, Gahan ME, McArthur J, Lwein SR, Hoy JF, Wesse-lingh SL. Exposure to dideoxynucleosides is reflected in low-ered mitochondrial DNAin subcutaneousfat.JAcquir Immune Defic Syndr 2002; 30:271-277. (Pubitemid 34774074)
16. Childs EA, Lyles RH, Selnes OA, Chen B, Miller EN, Cohen BA, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999; 52:607-613. (Pubitemid 29075612)
17. Tagliati M, Grinnell J, Godbold J, Simpson DM. Peripheral nerve function in HIV infection: clinical, electrophysiologic, and laboratory findings. Arch Neurol 1999; 56:84-89. (Pubitemid 29046913)
18. Cherry CL, Skolasky RL, Lal L, Creighton J, Hauer P, Raman SP, et al. Antiretroviral use and other risks for HIV-associated neuro- pathiesinaninternationalcohort. Neurology2006; 66:867 873. (Pubitemid 43739762)
19. Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Moorman AC, Wood KC, et al. Initiation of antiretroviral therapy at CD4 cell counts >350 cells/mm3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency. J Acquir Immune Defic Syndr 2008; 47:27-35. (Pubitemid 351619366)
20. Lichtenstein KA, Armon C, Baron A, Moorman AC, Wood KC, Holmberg SD. Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin Infect Dis 2005; 40:148-157. (Pubitemid 40053473)
21. Morgello S, Estanislao L, Simpson D, Geraci A, DiRocco A, Gerits P, et al. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank. Arch Neurol 2004; 61:546-551. (Pubitemid 38923745)
22. Smyth K, Affandi JS, McArthur JC, Bowtell-Harris C, Mijch AM, Watson K, et al. Prevalence of and risk factors for HIV-asso-ciated neuropathy in Melbourne, Australia 1993-2006. HIV Med 2007; 8:367-373. (Pubitemid 47163268)
23. Schifitto G, McDermott M, McArthur J, Marder K, Sacktor N, Epstein L, et al. Incidenceof and riskfactorsfor HIV-associated distal sensory polyneuropathy. Neurology 2002; 58:1764-1768. (Pubitemid 34663575)
24. Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, et al. HIV-associated neurologic disease incidence changes: multicenter AIDS Cohort Study, 1990-1998. Neurology 2001; 56:257-260. (Pubitemid 32095372)
25. Pettersen JA, Jones G, Worthington C, Krentz HB, Keppler OT, Hoke A, et al. Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiencysyndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol 2006; 59:816-824. (Pubitemid 43673159)
26. Corrao G, Zambon A, Bretu L, Botteri E, Leoni O, Contiero P. Lipid lowering drug prescription and the risk of peripheral neuropathy: an exploratory case-control study using auto-mated databases. J Epidemiol Community Health 2004; 58:1047-1051. (Pubitemid 39564208)
27. Banerjee S, McCutchan JA, Ances BM, Deutsch R, Riggs PK, Way L, Ellis RJ. Hypertriglyceridemia in combination antire-troviral-treated HIV-positive individuals: potential impact on HIV sensory polyneuropathy. AIDS 2011; 25:F1-F6.
28. Ances B, Rosario D, Vaida F, Marquie-Beck J, Ellis R, Simpson D, et al. Metabolic syndrome components as risk factors for distal sensory polyneuropathy [Paper #463]. CROI 2009; Montreal, Canada.
29. Sosenko JM, Boulton AJM, Gadia MT, Ward JD, Skylar JS. The association between symptomatic sensory neuropathy and body stature in diabetic patients. Diabetes Res Clin Pract 1988; 4:95-98. (Pubitemid 18025801)
30. Cherry CL, Affandi JS, Imran D, Yunihastuti E, Smyth K, Vanar S, et al. Age and height predict neuropathy risk in patients with HIV prescribed stavudine. Neurology 2009; 73:315-320.
31. Eron J, Smeaton L, Fiscus S, Gulick R, Currier J, Lennox J, et al. The effects of protease inhibitor therapy on human immuno-deficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850). Am J Infect Dis 2000; 181:1622-1628. (Pubitemid 30387753)
32. Robbins G, DeGruttola V, Shafer R, Smeaton L, Snyder S, Pettinelli C, et al. Comparison of sequential three-drug regi-mens as initial therapy for HIV-1 infection. N EnglJ Med 2003; 349:2293-2303. (Pubitemid 37509737)
33. Fischl M, Ribaudo H, CollierA, Erice A, Giuliano M, Dehlinger M, et al. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immu-nodeficiency virusdisease. Am J Infect Dis 2003; 188:625-634. (Pubitemid 37115174)
34. Landay A, SpritzlerJ, Kessler H, Mildvan D, Pu M, Fox L, et al. Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor-or protease inhibitor-contain-ing antiretroviral regimen. Am J Infect Dis 2003; 188:1444-1454. (Pubitemid 37523929)
35. GulickR, Ribaudo H, ShikumaC, LustgartenS, SquiresK, Meyer W, et al. Triple-nucleoside regimens versus efavirenz-contain-ing regimens for the initialtreatmentofHIV-1 infection. N Engl J Med 2004; 350:1850-1861.
36. Riddler S, Haubrich R, DiRienzo G, Peeples L, Powderly W, Klingman K, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N EnglJ Med 2008; 358:2095-2106. (Pubitemid 351679596)
37. Simpson DM, Kitch D, Evans SR, McArthur J, Asmuth DM, Cohen B, et al. HIV Neuropathy Natural History Cohort Study: assessment measures and risk factors. Neurology 2006; 66:1679-1687. (Pubitemid 43964622)
38. Ellis R, EvansSR, Clifford D, Moo L, McArthurJ, CollierA, et al. Clinical validation of the neuroscreen. J Neurovirol 2005; 11:503-511. (Pubitemid 43123769)
39. Evans S, Li L. A comparison of goodness of fit tests for the logistic GEE model. Statist Med 2005; 24:1245-1261. (Pubitemid 40485761)
40. Watters MR, Poff PW, Shiramizu BT, Holck PS, Fast KM, Shikuma CM, et al. Symptomatic distal sensory polyneuropathy in HIV after age 50. Neurology 2004; 62:1378-1383. (Pubitemid 38526052)
41. Ellis RJ, Rosario D, Clifford DB, McArthur JC, Simpson D, Alexander T, et al. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy. Arch Neurol 2010; 67:552-558.
42. Cherry CL, Affandi JS, Brew BJ, Creighton J, Djauzi S, Hooker DJ, et al. Hepatitis C seropositivity is not a risk factor for sensory neuropathy among patients with HIV. Neurology 2010; 74:1538-1542.
43. Gaist D, Jeppesen U, Andersen M, Garća Rodŕguez LA, Hallas J, Sindrup SH. Statins and risk of polyneuropathy: a case-control study. Neurology 2002; 58:1333-1337. (Pubitemid 34507158)